Comparative effectiveness, especially in its new guise of patient-centered outcomes research, is all the rage in US policy circles. Will it really make a difference to healthcare? Mark Ratner reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zhu, J. et al. JAMA 307, 1593–1601 (2012).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ratner, M. The gatekeepers of effectiveness. Nat Biotechnol 30, 482–484 (2012). https://doi.org/10.1038/nbt.2265
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2265
This article is cited by
-
Amgen best-seller challenged by generics
Nature Biotechnology (2013)